Notwithstanding various setbacks, several MDM2 inhibitors have now progressed into late-stage scientific advancement. New strategies have also been developed to improve the efficacy of MDM2 inhibitors and to mitigate their on-concentrate on toxicity. In this critique, we summarize the progress and worries in the development of the MDM2 targeted therapy. https://seanv852msw6.digitollblog.com/profile